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High-throughput sequencing (HTS) has revolutionized genetics by enabling the detection of
sequence variants at hitherto unprecedented large scale. Despite these advances, however,
there are still remaining challenges in the complete coverage of targeted regions (genes, exome
or genome) as well as in HTS data analysis and interpretation. Moreover, it is easy to get over-
whelmed by the plethora of available methods and tools for HTS. Here, we review the step-by-
step process from the generation of sequence data to molecular diagnosis of Mendelian dis-
eases. Highlighting advantages and limitations, this review addresses the current state of
(1) HTS technologies, considering targeted, whole-exome, and whole-genome sequencing on
short- and long-read platforms; (2) read alignment, variant calling and interpretation; as well as
(3) regulatory issues related to genetic counseling, reimbursement, and data storage.
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1 | INTRODUCTION
Prior to the current genomics era, exon-by-exon Sanger sequencing1
has been used for the sequence analysis of a single or a few genes. In
the last decade, while Sanger sequencing has remained the gold stan-
dard for confirming sequence variants, high-throughput sequencing
(HTS), also known as next-generation sequencing (NGS) has revolu-
tionized genetics by massive parallelization of sequencing reactions,
leading to a throughput several orders of magnitude higher than
Sanger sequencing.2 This high throughput allows to sequence a spe-
cific panel of genes (targeted sequencing, TS), the entire genome
(whole-genome sequencing, WGS) or its coding part (whole-exome
sequencing, WES) in a matter of hours to days, depending on the
technology and protocol used. The applied HTS technologies and
analysis pipelines, however, determine not only the time frame but
also the sensitivity/recall, precision, and disk footprint of variant call-
ing as well as the type of detectable sequence variants. It is therefore
of particular importance to be aware of the available HTS methods
and analysis tools for a best practice workflow in clinical sequencing.
Here, according to the recent literature and our own data, we
review the workflow from sequence data generation to molecular
diagnosis of Mendelian diseases (Figure 1), showing the advantages
and limitations of the most widely used HTS technologies and analy-
sis tools. Our review is divided into 3 main sections: (1) HTS technol-
ogies, (2) data analysis and interpretation, and (3) regulatory issues.
Accordingly, the first section addresses the current state and future
trends of HTS technologies, considering TS, WES, and WGS on
short- and long-read platforms. The second section overviews read
alignment (ie, mapping of reads to the reference genome) as well as
the ability to call different types of genomic sequence variants, such
as single-nucleotide variants (SNVs), small insertions and deletions
(indels, ≤50 bp), copy number variations (CNVs, >50 bp), and short
tandem repeats (STRs). The filtering and interpretation of called
sequence variants are addressed in this section as well. We focus on
a selection of software tools, being aware that laboratories may use
their own in-house data analysis and interpretation pipeline. The third
section is concerned with regulatory issues related to geneticSylvan M. Caspar and Nicolo Dubacher contributed equally to this work.
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counseling, reimbursement, and data storage. A glossary including
abbreviations is provided (Table 1).
2 | HIGH-THROUGHPUT SEQUENCING
TECHNOLOGIES
2.1 | Targeted sequencing
Genes of interest, so-called gene panels, can be enriched and
sequenced simultaneously by TS, which serves as an inexpensive and
rapid first-tier test with compatibility to benchtop short-read
sequencers (eg, Illumina MiSeq/NextSeq and Thermo Fisher Scientific
Ion PGM/Proton) and with especially high read depth of targeted
regions (Table 2). Consequently, TS enables sequence variant detec-
tion in samples with very low non-reference allele frequencies caused
by germline mosaics or clonal complexity of tumors.3,4 Moreover, the
use of disease-related gene panels facilitates the interpretation of
detected sequence variants and minimizes the chance of incidental
findings.5 According to the guidelines and recommendations of the
American College of Medical Genetics and Genomics (ACMG), only
genes with a scientifically sufficiently supported role in disease
should be included in a clinical gene panel.6
Limitations of TS include the difficulty of detecting clinically rele-
vant sequence variants, especially CNVs, in regions with an insuffi-
cient number of reads (ie, below the limit of variant calling) resulting
in discontinuous coverage (<100%) (Table 2). Incomplete coverage
can result from poor enrichment of GC-rich regions such as first
exons and from the absence of probes used for enrichment
(Figure 2).7 Furthermore, due to the identification of novel gene-
disease associations, gene panels require updates, especially in dis-
eases with incompletely understood molecular basis. Thus, TS may be
inconclusive in the case of negative results, providing no diagnosis
and requiring a different gene panel or an additional method for CNV
detection, or second-tier sequencing (WES and/or WGS). Updating
gene panels can be avoided by sequencing all (known) genes
(~25 000) applying WES or WGS.
2.2 | Whole-exome sequencing
As the exome encompasses ~2% of the human genome but harbors
~85% of all described disease-causing sequence variants,8,9 WES aims
to sequence the coding exons of all our known genes, that is, consid-
erably more than TS. The so-called clinical exome encompasses
~5000 disease-associated genes (eg, Agilent SureSelect Focused
Exome, Illumina TruSight One and Roche NimbleGen SeqCap EZ
High-throughput sequencing
(Panel, WES, WGS)
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FIGURE 1 Flow chart summarizing the
process from sequencing to diagnosis,
including associated challenges during
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analysis; MLPA, multiplex ligation-
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variants, sequence variants; VUS,
variants of unknown significance; WES,
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TABLE 1 Glossary and abbreviations
BAM (binary alignment map): file format for storing sequence reads aligned to the reference genome (compressed binary representation of SAM).
Benchmark reference materials: samples with known and validated sequence variants, which can be used for the benchmarking and evaluation of
sequencing platforms and software tools.
Bioinformatic pipelines: workflow combining a variety of software tools for biological data analysis.
Clinical exome: HTS restricting sequencing to disease-associated genes.
ClinVar: a freely accessible, public archive for the clinical interpretation of human sequence variants (ncbi.nlm.nih.gov/clinvar).
CNV: copy number variation (deletions and duplications >50 bp).
CRISPR-Cas9-targeted enrichment: a novel, amplification-free enrichment technique that employs the CRISPR-Cas9 system for specific targeting of
multiple genomic loci.105
De novo assembly for CNV detection: approach to identify SVs by merging and ordering unaligned reads to reassemble the original sequence from which
the reads were sampled.
Disk footprint: storage footprint on a disk expressed in bytes such as mega- (MB), giga- (GB) or terabytes (TB).
Enrichment bias: in HTS with a hybridization-based capture and/or amplification step, certain genomic regions are enriched with different efficiency (eg,
due to differences in GC content). Indeed, GC-rich regions are difficult to enrich, leading to a below-average number of reads and to incomplete
coverage of targeted regions (genes, exome or genome).
Enrichment kits: reagent kits for capturing pre-selected (targeted) genomic regions of interest (eg, exome).
ExAC/gnomAD: the Exome Aggregation Consortium (ExAC; exac.broadinstitute.org) and the Genome Aggregation Database (gnomAD; gnomad.broadin
stitute.org) are large-scale sequencing projects currently containing 60 706 exomes and 123 136 exomes/15 496 genomes, respectively. These data
sets serve as the reference for population frequencies but may include individuals with late-onset or unrecognized disease.
FASTQ format: text-based format for storing both biological sequences (usually nucleotide sequences) and their corresponding quality scores.
FN (false-negative sequence variant): variant missed by variant calling, despite being present. The goal of clinical sequencing should be to have zero FNs
as they could lead to missed diagnoses.
FP (false-positive sequence variant): variant detected by variant calling, despite being absent. The number of FPs can be reduced by appropriate (eg,
frequency-based) variant filtering.
GC-rich regions: genomic regions containing high numbers of guanine (G) and cytosine (C). Due to the base stacking, GC-rich genomic regions are
particularly stable and hence more difficult to enrich.
HGMD: the commercial Human Gene Mutation Database constitutes a comprehensive core collection of data on germline sequence variants in nuclear
genes underlying or associated with human inherited disease (portal.biobase-international.com). The less up-to-date public version of HGMD is freely
available for academic institutions/non-profit organizations (www.hgmd.cf.ac.uk).
HPO: the Human Phenotype Ontology is a database aiming to provide a standardized vocabulary of phenotypic abnormalities encountered in human
disease (human-phenotype-ontology.github.io).
HTS: high-throughput (formerly next-generation) sequencing.
Incidental findings: sequence variants with potential health or reproductive importance but unrelated to the clinical phenotype for which sequencing
was performed.
Indels: small insertions and deletions (≤50 bp).
Interpretation databases: Examples for SNVs/indels: OMIM, HGMD, ClinVar, LSDB, ExAC/gnomAD; for CNVs: DGV (dgv.tcag.ca).
Interpretation software: Examples for SNVs/indels: Alissa Interpret (agilent.com/lifesciences/alissa; suitable for CNVs as well), Ingenuity Variant Analysis
(qiagenbioinformatics.com/products/ingenuity-variant-analysis), Exomiser/Genomiser (exomiser.github.io/Exomiser), NxClinical (biodiscovery.com/
nxclinical; suitable for CNVs as well), VarSeq (goldenhelix.com/products/VarSeq); for CNVs: InHelix (diploid.com), Nexus copy number
(BioDiscovery); for manual interpretation: Alamut Visual (interactive-biosoftware.com), Varsome (varsome.com).
LRS: long-read sequencing.
LSDB: locus specific mutation database (hgvs.org/locus-specific-mutation-databases).
Mappability: computed value giving the inverse of the number of times that a read maps to the genome for a given read length and number of allowed
mismatches (eg, m = 2). A mappability of 1 indicates unambiguous mappable regions, whereas a mappability <1 indicates regions which tend to
produce ambiguous mappings.33
Non-reference allele: allele with sequence variant, that is, with sequence differing from the reference genome.
OMIM: Online Mendelian Inheritance in Man is a freely available, comprehensive, authoritative compendium of human genes and genetic phenotypes,
containing information on all known Mendelian disorders and currently over 15 000 genes (omim.org).
ONT: Oxford Nanopore Technologies (nanoporetech.com).
PacBio: Pacific Biosciences (pacb.com).
Paired-end mapping: approach to identify SVs by evaluating the span and orientation of paired-end reads. CNVs are indicated by read pairs with
mapping spans inconsistent with the expected insert size.
Precision: analysis quality measure (TP/[TP + FP]), analogous to positive predictive value.
Random monoallelic expression (MAE): only 1 of 2 alleles of a gene is actively transcribed, while the other allele is silent. MAE can occur in a random
fashion, varying in an interindividual-, tissue- and/or cell-type-specific manner87 and its evaluation is assisted by the database of monoallelic
expression (dbMAE, mae.hms.harvard.edu), containing information on tissue-specific expression patterns of autosomal genes.88
Read alignment: mapping/assigning of raw short or long reads (sequencer output stored in FASTQ or related formats) to the reference genome.
Software examples for the alignment of short reads: BWA-MEM,63 Isaac,65 GENALICE MAP (genalice.com).60
Read depth: number of aligned sequencing reads covering a specific genomic position.
(Continues)
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MedExome), thereby covering only ~20% of the entire exome and
thus requiring additional analyses if the disease-causing sequence
variant remains undetected.10,11 In contrast, WES not only covers
exons of already disease-associated genes but also allows for the
identification of novel gene-disease associations in diseases with yet
unknown molecular basis in a cost-effective way.12,13 It is therefore
not surprising that WES is widely used and has been advocated as a
first-tier test instead of TS.14,15 The cost efficiency of WES makes
trio analysis feasible (ie, sequencing the patient and his/her parents),
which facilitates data interpretation and increases the diagnostic yield
considerably (from ~20% to ~30%).16,17
WES data analysis can be limited in silico to a gene panel (genes
of interest) and subsequently expanded if necessary, thereby reduc-
ing the potential for the discovery of incidental/secondary find-
ings.18,19 Although WES can detect more sequence variants than TS,
WES has similar limitations as TS (Figure 2, Table 2). Accordingly,
WES may fail to cover poorly enriched parts of the exome and hence
to detect clinically relevant sequence variants, that is, ~400 exonic
disease-causing variants listed in HGMD (portal.biobase-international.
com).7 The incomplete coverage of WES may be improved by com-
bining enrichment kits (eg, Agilent SureSelect, Illumina TruSeq Cap-
ture, and Roche NimbleGen SeqCap EZ) or by using a high
concentration of capture probes that cover difficult-to-enrich
regions.20–23
2.3 | Whole-genome sequencing
WGS has the advantages of the most continuous coverage and iden-
tifying sequence variants throughout the genome. These advantages
enable WGS (1) to be a better WES7; (2) to detect non-exonic
sequence variants7,21 and (3) to improve CNV detection,7,24 leading
to increased diagnostic yield over WES.25–28
WGS data interpretation, as in WES, may initially focus on a
region of interest by applying in silico gene panels. To date, deep
intronic, intergenic, and regulatory sequence variants are difficult
or impossible to interpret at the DNA level only.29 However, even
such sequence variants can be of importance in the near or distant
future, adding a superior value to WGS data and putting the
higher costs of WGS into a lifetime perspective. This superior
value of WGS can be recognized in the emerging field of pharma-
cogenetics.30 Pharmacogenetic predisposition, which can be
obtained by subsequent filtering of appropriate HTS data, is clini-
cally highly relevant, because it can play a pivotal role in the suc-
cess or failure of a pharmacological therapy. Notably, some
pharmacogenetically-relevant sequence variants, such as a single
nucleotide polymorphism (SNP) in the promoter region of VKORC1
(rs9923231) causing low-warfarin-dose phenotype31 or structural
variations (SVs) affecting drug targets,32 can readily be detected
by WGS but not by WES. The limitation of WGS is mainly
TABLE 1 (Continued)
Read-depth analysis: approach to identify CNVs by comparing the read depth of genomic regions in a sample to its own average read depth or to the
read depth of the same region in one or multiple control samples.
Reference genome: the current human reference genome (assembly of a number of donors) is GRCh38 (the Genome Reference Consortium human
genome build 38) or hg38 (equivalent version). Reference genomes are improved by the Genome Reference Consortium and these improvements
should lead to more accurate genomic analyses.106 The previous human reference genome GRCh37/hg19 is still widely used.
RefSeq: the Reference Sequence collection (ncbi.nlm.nih.gov/refseq) provides a comprehensive, non-redundant, well-annotated set of sequences,
including genomic DNA, transcripts, and proteins. RefSeq sequences form a foundation for medical, functional, and diversity studies.
SAM (sequence alignment map): file format for storing biological sequences aligned to the reference genome. It is widely used for storing data, such as
nucleotide sequences. The format supports short and long reads.
Sensitivity/recall: analysis quality measure (TP/[TP + FN]), analogous to true positive rate or probability of detection.
SNP (single-nucleotide polymorphism): variation in a nucleotide at a single specific position among individuals, occurring with appreciable relative
frequency (e.g. >1%) within a population (not to be confused with SNV).
SNV (single-nucleotide variant): variation in a nucleotide at a single specific position between individual and reference genomes without any frequency
limitation (not to be confused with SNP). dbscSNV is a database for SNVs within splicing consensus regions.82
Split reads: approach to identify SVs by investigating breakpoints in reads split into two parts and aligned separately to the genome (different position
and/or orientation).
SRS: short-read sequencing.
SRS dead zone: genomic region for which multiple matches of short-read sequencing reads exist, making unambiguous mapping impossible.35
STR (short tandem repeat): DNA sequence with a DNA motif of a few base pairs repeated in tandem (also known as microsatellite).
SV (structural variation): sequence variant affecting the structure of a chromosome (eg, copy number variations, insertions, and translocations).
TP (true-positive sequence variant): sequence variant which are present and detected by variant calling.
Trio analysis: HTS data of an index case and his/her parents is used to facilitate the detection of disease-causing sequence variant(s).
TS (targeted sequencing): a rapid and cost-effective way to detect known and novel variants in selected/enriched sets of genes or genomic regions
(specified in gene panels).
Variant calling: process of identifying sequence variants by detecting positions differing between sample sequence and reference genome. Software
examples for SNVs/Indels: GATK-HC,64 Isaac,65 or GENALICE MAP (genalice.com); for CNVs: CNVnator,69 BreakDancer,70 LUMPY,71 Manta,72 Cor-
tex73; for STRs: lobSTR,77 ExpansionHunter,78 HipSTR,79 or STRetch.80
(g)VCF: (genomic) Variant Call Format used for storing genomic sequence variants. (g)VCF files contain meta-information lines, a header line, and data
lines containing information about the called sequence variants and their positions in the genome.
VUS: sequence variants of unknown significance.
WES: whole-exome sequencing.
WGS: whole-genome sequencing.
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determined by the sequencing read length leading to uncertain
(<1) mappability (Table 2).
2.4 | Short-read sequencing
TS, WES, and WGS have traditionally been performed using short-
read sequencing (SRS), also known as second-generation sequencing.
SRS typically produces reads that are 100 to 400 bp in length,
depending on the used technology. The current SRS market leader is
Illumina (illumina.com) but also other manufacturers offer SRS
sequencers, such as Thermo Fisher Scientific (thermofisher.com) and
Beijing Genomics Institute (bgi.com) offering Ion Torrent and proprie-
tary BGISEQ (former Complete Genomics) platforms, respectively.
SRS is typically based on library preparation by random fragmen-
tation of input DNA and subsequent adapter ligation, followed by
massively parallel sequencing of adapter-ligated fragments.2 While
the main advantages of SRS include high-throughput, low per base
cost and low raw-read error rate (Table 2), the common limitation of
Unique DNA sequence (mappability =1)
Repetitive/homologous DNA sequence (mappability <1)
LRS (~7-10-kb-read length)
SRS (~150-bp-read length)
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Reads
Reads ??????
Not illustrated genomic regions
(A)
(B)
FIGURE 3 Schematic representation of
read alignment when using SRS
compared to LRS. (A) SRS is exemplified
by 150-bp short reads. Note that
repetitive/homologous regions longer
than the read length cause ambiguous
alignment, that is, mappability <1.
(B) LRS is exemplified by multi-kb long
reads. Note that long reads can cover
unique DNA sequences flanking
repetitive/homologous regions, enabling
unambiguous alignment, that is,
mappability = 1. LRS, long-read
sequencing; Ref., reference genome;
SRS, short-read sequencing
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FIGURE 2 Coverage difference between WES and WGS exemplified for 2 genes (adapted and modified from Reference 7). (A) Not all exons are
captured leading to low/insufficient read depth in WES in contrast to WGS. (B) GC-rich (77%) exon 2 of KLF2 is completely covered by PCR-free
WGS and almost completely by WGS with PCR, while a large gap in coverage is present in WES. Coverage tracks are visualized by the Integrative
Genomics Viewer (IGV, broadinstitute.org/igv). For abbreviations, see Figure 1 and Table 2. *Designed target region of Agilent SureSelect v5 + UTR
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all SRS platforms is the short read length, leading to read alignment
difficulties (Figure 3). Indeed, bioinformatic alignment of reads match-
ing to more than 1 genomic location due to sequence homology
(mappability <1) is ambiguous and can lead to misalignments as well
as to false-positive and false-negative variant calling.33–35
To increase the awareness of SRS limitations, we filtered all
201 461 unique autosomal and X-chromosomal coding exons listed in
RefSeq (ncbi.nlm.nih.gov/refseq, version December 2013) by 3 different
criteria potentially affecting SRS read depth and/or variant calling. The
first criterion was mappability, identifying coding exons that have at
least 1 base with mappability <1 in 75-bp short sequences. The second
criterion was the presence of common CNVs overlapping with the ana-
lyzed autosomal and X-chromosomal coding exons because it may lead
to a lower (deletions) or higher (duplications) read depth, which may
affect the calling of non-CNV variants. We therefore filtered out exons
overlapping with common CNVs listed in the Database of Genomic
Variants (DGV, dgv.tcag.ca, version July 2015)36 detected in >90 indi-
viduals. The third criterion identified coding exons with errors in the
reference genome, that is, updated in GRCh38/hg38 compared to
GRCh37/hg19, as these can lead to erroneous alignment and variant
calling. According to all 3 criteria, in ~12% of all coding exons listed in
RefSeq special caution is needed in variant calling and interpretation of
SRS data (Figure 4). Moreover, ~2% of all exons have 100% of positions
or at least 1 250-bp-long contiguous region with mappability <1 defin-
ing the SRS dead zone35 as well as ~17% of all 75-bp-long genomic
regions have a mappability <1. Taken together, in addition to SRS
appropriate complementary approaches such as long-read sequencing
(LRS) have to be considered, at least for regions with mappability <1.
2.5 | Long-read sequencing
The read and mappability limitations of SRS can be overcome by
using LRS. LRS with multi-kb-long reads facilitates unambiguous
alignment to a reference genome due to the increased ability of long
reads to completely span large complex, repetitive or homologous
regions (Figure 3). By using LRS, the unambiguously mappable region
of the genome can therefore be increased, minimizing clinically rele-
vant false-negative results.37 So far, 2 LRS technologies have been
introduced, with real and synthetic long reads.
Real LRS, also known as third-generation sequencing, is typified
by single-molecule sequencing of Pacific Biosciences (PacBio, pacb.
com) as a market leader and Oxford Nanopore Technologies (ONT,
nanoporetech.com) as a newcomer, both of which are able to
sequence GC-rich regions with uniform coverage and to determine
DNA base modifications without special treatment. PacBio uses
single-molecule, real-time sequencing, generating reads with an aver-
age length of 10 to 15 kb.38 PacBio sequencers have been used for
different purposes such as de novo genome assembly, accurate geno-
typing of difficult-to-sequence regions, detection of CNVs and other
SVs, discovery of transcriptome complexity and novel isoforms, and
detection of methylation status.37–40 The latest PacBio sequencer
(Sequel) has been introduced to increase throughput and cost effec-
tiveness but both remain considerably lower than in SRS.
The PacBio competitor ONT exploits the voltage change differ-
ence among nucleotides passing through a biological nanopore. ONT
reads are on average 7 to 8 kb long41 and can be generated on
devices of different sizes such as the portable mobile-phone-sized
MinION (1 flowcell) or the benchtop PromethION (48 flowcells) capa-
ble of sequencing a whole human genome.42 In addition to PacBio-
like applications,41,43,44 the MinION has successfully been used for
infectious disease outbreak surveillance in remote regions45,46 and
for phasing of cancer-related gene amplicons with especially high
read depth comparable to short-read TS.47,48 Despite having clear
advantages in mappability and epigenetic mark detection over SRS,
real LRS is not yet routinely applied due to its significantly lower
throughput and higher per sample sequencing costs.49 Furthermore,
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FIGURE 4 Short-read sequencing of RefSeq coding exons. (A) Percentage or number of exons with potentially affected (red) and unaffected
(gray) read depth alignment and/or variant calling in short-read, whole-genome sequencing due to ambiguous 75-mer mappability
(mappability<1), the presence of common copy number variations (CNVs) and the difference between the GRCh37 (ncbi.nlm.nih.gov/assembly/
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PacBio and ONT both have high raw read error rates of ~10%.38,41
As such errors are distributed randomly, their effect on consensus
sequence and variant calling, however, can be minimized by increas-
ing read depth and reading a template molecule multiple times
(PacBio) or twice (ONT).49 On the horizon are other real LRS plat-
forms such as the mobile-phone-attachable SmidgION from ONT,
solid-state nanopores from Hitachi50 and the former Genia platform
now owned by Roche (sequencing.roche.com), promising new possi-
bilities for clinical applications.
Synthetic LRS is typified by long-read library preparation of Illu-
mina (TruSeq Synthetic Long-Read DNA Library Preparation Kit,
illumina.com) or 10X Genomics (10xgenomics.com), indexing sheared
long fragments prior to SRS and bioinformatically merging short to
long reads. As synthetic LRS is available on an SRS platform for a
fraction of the cost, while offering similar results as real long reads,
synthetic LRS is a promising alternative to real LRS. For example, syn-
thetic long reads have successfully been applied to genome haplotyp-
ing and diploid de novo assemblies,51,52 discovery of large genomic
inversions,53 and genome-wide reconstruction of complex SVs.54
Although synthetic LRS may miss regions detectable by real LRS, it is
predictable that LRS, synthetic or real, will soon find broad applica-
tions in clinical genetics.
3 | READ ALIGNMENT AND VARIANT
CALLING
To detect sequence variants, the HTS output (short or long reads),
stored in FASTQ or related formats, requires unambiguous read align-
ment to the reference genome (generating SAM/BAM files) and accu-
rate variant calling (stored in (g)VCF files) using appropriate
bioinformatic pipelines. As bioinformatic tools are typically specialized
in a certain step of data analysis or have different performance,55,56 a
combination of appropriate tools is recommended to detect different
types of sequence variants and to minimize clinically relevant false-
negative results (ie, to zero as missing the disease-causing sequence
variant leads to missing the molecular diagnosis). While the perfor-
mance of HTS platforms has frequently been addressed in the last
years, the performance of bioinformatic tools, especially for variant
interpretation and LRS data analysis, is still a matter of ongoing
research involving benchmark reference materials.57–61
3.1 | SNVs and insertions/deletions
The current de facto standard for the alignment of short reads and
the calling of SNVs and indels is the BWA/GATK best practices
pipeline,62 which combines the read aligner BWA-MEM63 and the
variant caller GATK-HC.64 As the computation time (~93 hours) and
disk footprint (~254 GB) of BWA/GATK (version 3.5) is less suitable
for large WGS data sets (60×), alternative tools such as Illumina’s
Isaac65 and GENALICE MAP (genalice.com) have been introduced,
offering faster analyses with reduced output file sizes.60 Indeed, in
our benchmarking study, GENALICE MAP showed ultrarapid speed
(~1 hour) and superior low disk footprint (~6 GB) with BWA/GATK-
like sensitivity for 60× short-read WGS data.60 However, the run
time of BWA/GATK may be accelerated 5× by the upcoming GATK
version 4.0 and/or the DRAGEN platform (edicogenome.com) or
compressive methods such as CORA,66 allowing current BWA/GATK
users to move on from TS or WES to WGS data analyses.
3.2 | Copy number variations
CNVs and copy neutral rearrangements such as inversions and trans-
locations are SVs affecting large genomic segments.67 Except for the
software GROM (Genome Rearrangement OmniMapper), a recently
introduced all-in-one solution to detect SNVs, indels, CNVs, and
other SVs,68 algorithms used for calling of SNVs and indels are not
suited for the detection of larger sequence variants, requiring dedi-
cated algorithms for CNV detection. Calling of CNVs from HTS data
can be achieved by different approaches such as read-depth analysis,
paired-end mapping, split reads, and de novo assembly.24 A wide vari-
ety of CNV-calling tools uses 1 or several of these strategies, for
example, CNVnator (read depth),69 BreakDancer (paired-end
mapping),70 LUMPY and Manta (paired-end mapping and split
reads),71,72 or Cortex (de novo assembly).73 Except for read-depth-
based tools, CNV calling strategies are only applicable for WGS data,
enabling the detection not only of CNVs but also of copy neutral SVs
at base-pair resolution.74 For CNV detection in TS and WES data,
dedicated tools have been developed,75 taking the enrichment bias
into account, however, without achieving the accuracy observed in
WGS data.24,76 As CNV calling tools differ in their performance and
hence users need to combine multiple algorithms, no de facto stan-
dard has been established for CNV detection.
3.3 | Short tandem repeats
STR expansions are highly relevant in clinical genetics but difficult to
genotype accurately by SRS due to low-quality calls, very high GC
content (as in fragile X syndrome) and/or expansions longer than the
read length leading to ambiguous alignments that can be overcome
by LRS. A number of software tools attempting to overcome SRS
challenges for STR genotyping have recently been introduced, such
as lobSTR,77 ExpansionHunter,78 HipSTR,79 and STRetch,80 demon-
strating that also SRS data can lead to useful STR profiles. While the
interpretation of STR expansions with known disease association is
straightforward, the variant filtering and interpretation of other
sequence variant types can be challenging.
4 | VARIANT FILTERING AND
INTERPRETATION
HTS outputs about one called variant per 1000 bp of sequenced
genome compared to the reference genome, leading to ten thousands
and millions of sequence variants in WES and WGS, respectively. For
time-consuming manual evaluation, appropriate filtering can help to
reduce these large numbers by distinguishing pathogenic sequence
variants from (likely) benign ones (Figure 1).81 In silico gene panels
can restrict sequence variants to the genes of interest. Gene-disease
and variant-disease associations may be found in the literature (ncbi.
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nlm.nih.gov/pubmed) and databases such as OMIM (omim.org),
HGMD (portal.biobase-international.com), ClinVar (ncbi.nlm.nih.gov/
clinvar), and LSDB (hgvs.org/locus-specific-mutation-databases).
SNVs and indels can be prioritized based on their population fre-
quency (eg, ExAC/gnomAD, gnomad.broadinstitute.org), phylogenetic
conservation (eg, PhastCons, SiPhy), and potential effect on splicing
(eg, Ada and RF scores in dbscSNV),82 protein function or structure
(eg, SIFT, PolyPhen2, MutationTaster2). For the prioritization of
CNVs, their size and population frequency (eg, DGV) can be used.
However, prioritization scores and predicted variant effects should
never be automatically associated with pathogenicity, requiring man-
ual expert review and intepretation.83
Several filtering and interpretation tools exist for the prioritiza-
tion of annotated SNV and indel variants,84 many of which have been
reviewed elsewhere.81,83 In contrast, only a few dedicated software
tools are available for ranking the large amount of CNVs detected by
genome-wide HTS (s. interpretation software examples in Table 1).85
Intergenic CNVs disrupting the boundaries of topologically associat-
ing domains (TADs), in which genes have a higher probability of phys-
ical interaction,86 should be included into a comprehensive CNV
interpretation. In the interpretation of pathogenicity (especially in
segregation analyses and genetic counseling), disease onset, parental
mosaicism, dual molecular diagnoses (modifier), and random autoso-
mal monoallelic expression87,88 (Table 1) should also be considered.
Moreover, although the accurate prediction of splicing defect is cur-
rently challenging and needs the development of better in silico tools
in the future, it is clinically relevant to consider the possibility of
aberrant splicing for any intronic and exonic sequence variants
detected in diseases.89–94 As a considerable number of new gene-
disease and variant-disease associations have been reported annually,
the regular reevaluation of HTS data using current knowledge is indi-
cated for unsolved cases with suspected Mendelian disorder.10,11
Trio and segregation analyses, if available, can be carried out not
only to provide further evidence for the disease association of
detected sequence variant(s) but also to determine whether sequence
variants are de novo or inherited, thereby implicating and enabling
the recognition of at-risk relatives. Furthermore, the interpretation of
rare or novel sequence variants might be facilitated by collaborative
efforts and global-scale data sharing of geno- and phenotypic pro-
files, which can bring together identical or similar cases and hence
increase significance through recurrent findings. One such possible
platform is Matchmaker Exchange (matchmakerexchange.org), which
includes multiple appropriate databases (eg, DECIPHER, decipher.
sanger.ac.uk) and matching tools (eg, Gene Matcher, genematcher.
org), allowing the connection between patients, clinicians, and
researchers from around the world.93 Successful data sharing, how-
ever, requires the use of standardized terms for describing clinical
phenotypes, for which initiatives have been developed such as the
Human Phenotype Ontology (HPO, human-phenotype-ontology.
github.io).
The most comprehensive interpretation of sequence variants
requests not only well-curated databases, segregation analyses, and
data sharing but also appropriate functional analyses, for example,
to assess the effect of variants on splicing and/or gene expres-
sion.29,94,95 Nevertheless, despite the most comprehensive
interpretation, variants of unknown significance (VUS) will remain
one of the most frequent entities for years in the current genomics
era.81 Sequence variants to be reported might be confirmed by
Sanger sequencing (for SNVs, indels, and breakpoints of large dele-
tions), MLPA or quantitative PCR (for CNVs) and/or fragment
length analyses (for STRs). Readers of genetic testing reports
should bear in mind that sequencing technologies, variant calling,
filtering, and interpretation differ among laboratories94 as well as
that incorrect connection between sequence variant and disease
could have fatal consequences to patient health and family
planning.83
5 | REGULATORY ISSUES: GENETIC
COUNSELING, REIMBURSEMENT AND DATA
STORAGE SAFETY
For clinical genetic testing with the purpose to identify the disease-
causing sequence variant(s), an informed consent of the person being
tested (or his/her legal representative) is required. Clinical genetic
testing (not to be confused with direct-to-consumer genetic testing)
should be preceded and followed by professional genetic counseling
(acpm.org/?GeneticTestgClinRef) including appropriate information
on incidental findings unrelated to the clinical indication but of medi-
cal value or utility, for example, for the prevention of a late-onset dis-
ease or for the identification and counseling of at-risk relatives. The
reporting of incidental findings in WES/WGS is a challenging subject,
for which the patient’s decision should be respected and the guide-
lines established by the ACMG may be consulted.18,19
The reimbursement for clinical genetic testing varies among
countries. Even when ordered by a qualified person (eg, medical
geneticist, primary care doctor) it is recommended to inquire of the
insurance company beforehand if costs are covered (ghr.nlm.nih.gov/
primer/testing/insurancecoverage). Furthermore, when it comes to
insurances there is a risk for genetic discrimination, which needs to
be prevented.96 Regulations are required in a way that both, patients
and the healthcare systems, can benefit from the scientific
advances.97 The goal should be toward the benefit of patients in
need while still being economically feasible.
With ever-increasing amounts of genetic data there are emerging
regulatory issues regarding data safety and storage. Although cloud
environments enable high-capacity data storage (eg, Amazon Web
Services, aws.amazon.com), there are legitimate concerns about the
privacy and security of sensitive cloud-stored genetic data,98 indicat-
ing the need for more secure and decentralized solutions (eg,
UnLynx).99 Data sharing, which facilitates genotype-phenotype corre-
lation, is subject to further discussions as it has been shown that
even after de-identification, re-identification of a single person is at
least partially possible by either STR100 or SNP genotyping.101
6 | CONCLUSIONS AND PERSPECTIVES
The workflow used in HTS impacts the diagnostic yield. Contrary to
expectations, whole does not equal whole in short-read WES and
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WGS. From a technical point of view, PCR-free WGS is not only the
most comprehensive SRS method but also the better WES as it pro-
vides the most uniform/complete coverage of the genome and covers
the exome better than WES.7 As a considerable number of coding
exons remain insufficiently covered by SRS, LRS is envisioned as the
future of sequencing. Until then, however, LRS could complement
SRS by sequencing of insufficiently covered regions, for the selection
of which CRISPR-Cas9-targeted enrichment could be considered.105
In addition to LRS, next-generation genome mapping on nanochannel
arrays (bionanogenomics.com) may enter clinical genetics enabling
the detection of large SVs.102 In the next years, the detection of
CNVs and STR expansions by appropriate HTS methods as well as
the combination of DNA and transcriptome sequencing will increase
the diagnostic yield.103
Fueled by technological advances, HTS has led to the current sit-
uation in which our ability to sequence is greater than our ability to
interpret the detected sequence variants. Indeed, the effects of VUS
and non-exonic sequence variants pose a challenge for variant inter-
pretation. Methods used for alignment, variant calling, and filtering
can considerably influence sequence variant detection. Thus, it is
recommended to use more than 1 independent data analysis pipeline
and to reevaluate unsolved cases to minimize clinically relevant false-
negative results. Exclusively relying on in silico interpretation tools is
dangerous, because, although powerful, they are not without fault
and not a replacement for expert review and functional analyses.104
HTS for clinical applications has not yet reached its full potential,
because of remaining technical (hardware and software) and regula-
tory issues. Especially an appropriate solution will have to be found
for data storage and safety because of ever-increasing amounts of
genomic data with lifetime value.
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